Thus, our finding that Paqr8 undergoes preferential CN gain and is upregulated in recurrent tumors across multiple GEM models, recapitulating the preferential CN gain of PAQR8 in recurrent breast cancers observed in patients, further suggests the hypothesis that Paqr8 promotes tumor recurrence and resistance to therapy. The gene discussed is PAQR8; the disease is breast cancer.